Inclisiran: A Novel Therapeutic for Long-Term Lowering of LDL Cholesterol?

By Connor Emdin
May 18, 2017

Elevated low-density lipoprotein cholesterol (LDL cholesterol) is a leading cause of coronary heart disease and death worldwide.1 When LDL cholesterol particles become oxidized, they can invade the endothelium of blood vessels and attract macrophages, forming atherosclerotic plaques. Over a lifetime, high levels of LDL cholesterol can lead to the formation of numerous unstable atherosclerotic plaques, potentially leading to myocardial infarction, stroke, and death from cardiovascular disease (CVD).2 Continue reading “Inclisiran: A Novel Therapeutic for Long-Term Lowering of LDL Cholesterol?”

New Guidelines for Statin Treatment

Statins for Prevention of Cardiovascular Disease in Adults

By Martina M. McGrath, MD
December 22, 2016

Cardiovascular disease (CVD) remains the leading killer of adults in the US, implicated in one out of every three deaths. Statins have shown significant benefit in secondary prevention of cardiovascular disease and mortality across a range of patient populations. Despite a large body of work, the data for primary prevention is less clear. Until now, the US Preventive Services Task Force (USPSTF) has not recommended statin therapy for primary prevention of CVD, but has instead suggested monitoring lipid levels as part of an overall CV risk assessment. ┬áIn November 2016, they produced a set of recommendations published in JAMA, along with several accompanying editorials. Patients with LDL cholesterol >190mg/dL and those with familial hypercholesterolemia are excluded as statin therapy is recommended with this degree of hyperlipidemia. Lifestyle modification advice is recommended for all patients. Continue reading “New Guidelines for Statin Treatment”